Inventor
ORENTAS RIMAS J
US33 patents
⚠️ This page may combine multiple inventors who share the name “ORENTAS RIMAS J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
LENTIGEN TECH INC
20 patentsUS10844128B2Nov 24, 2020
Compositions and methods for treating cancer with anti-CD123 immunotherapy
LENTIGEN TECH INC20 citations94
US10442867B2Oct 15, 2019
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
LENTIGEN TECH INC17 citations94
US10428141B2Oct 1, 2019
Compositions and methods for treating cancer with anti-ROR1 immunotherapy
LENTIGEN TECH INC15 citations94
US11103533B2Aug 31, 2021
Compositions and methods for treating cancer with anti-CD38 immunotherapy
LENTIGEN TECH INC7 citations84
US10550179B2Feb 4, 2020
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
LENTIGEN TECH INC6 citations84
US10501539B2Dec 10, 2019
Compositions and methods for treating cancer with anti-CD19 immunotherapy
LENTIGEN TECH INC8 citations84
US11242389B2Feb 8, 2022
Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
LENTIGEN TECH INC5 citations83
US11208455B2Dec 28, 2021
Compositions and methods for treating cancer with DuoCARs
LENTIGEN TECH INC6 citations83
US10689431B2Jun 23, 2020
Compositions and methods for treating cancer with DuoCARs
LENTIGEN TECH INC8 citations83
US11453719B2Sep 27, 2022
Compositions and methods for treating cancer with anti-ROR1 immunotherapy
LENTIGEN TECH INC2 citations73
US11802142B2Oct 31, 2023
Compositions and methods for treating cancer with DuoCARs
LENTIGEN TECH INC1 citations72
US12540179B2Feb 3, 2026
Compositions and methods for treating cancer with anti-ROR1 immunotherapy
LENTIGEN TECH INC0 citations62
US12391958B2Aug 19, 2025
Compositions and methods for treating cancer with anti-CD38 immunotherapy
LENTIGEN TECH INC0 citations62
US12365718B2Jul 22, 2025
Compositions and methods for treating cancer with DuoCARs
LENTIGEN TECH INC0 citations62
US12037403B2Jul 16, 2024
Compositions and methods for treating cancer with anti-CD123 immunotherapy
LENTIGEN TECH INC0 citations62
US11708408B2Jul 25, 2023
Compositions and methods for treating cancer with anti-CD19 immunotherapy
LENTIGEN TECH INC0 citations62
US11680103B2Jun 20, 2023
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
LENTIGEN TECH INC0 citations62
US12371490B2Jul 29, 2025
Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
LENTIGEN TECH INC0 citations61
US12193995B2Jan 14, 2025
Method to treat cancer with engineered T-cells
LENTIGEN TECH INC0 citations61
US12122831B2Oct 22, 2024
Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
LENTIGEN TECH INC0 citations61
US HEALTH
7 patentsUS9868774B2Jan 16, 2018
Anti-CD22 chimeric antigen receptors
US HEALTH36 citations93
US9790282B2Oct 17, 2017
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US HEALTH28 citations93
US10072078B2Sep 11, 2018
M971 chimeric antigen receptors
US HEALTH7 citations84
US10703816B2Jul 7, 2020
M971 chimeric antigen receptors
US HEALTH3 citations73
US11078286B2Aug 3, 2021
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
US HEALTH2 citations70
US11807682B2Nov 7, 2023
M971 chimeric antigen receptors
US HEALTH0 citations62
US12453780B2Oct 28, 2025
Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
US HEALTH0 citations60
LENTIGENTECHNOLOGY INC
3 patentsUS10543263B2Jan 28, 2020
Compositions and methods for treating cancer with anti-CD22 immunotherapy
LENTIGENTECHNOLOGY INC14 citations84
US10822412B2Nov 3, 2020
Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
LENTIGENTECHNOLOGY INC6 citations82
US11878052B2Jan 23, 2024
Compositions and methods for treating cancer with anti-CD22 immunotherapy
LENTIGENTECHNOLOGY INC1 citations61
THE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES
2 patentsUS10604583B2Mar 31, 2020
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
THE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES1 citations68
US11512138B2Nov 29, 2022
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
THE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES0 citations58